Field Medical Presents Breakthrough Trial Data at AF Symposium 2026, Highlights Next-Generation Ablation Technology
CARDIFF-BY-THE-SEA, CALIFORNIA: Clinical-stage medical technology company Field Medical, Inc. has unveiled late-breaking clinical data from its Field PULSE trial at the 2026 AF Symposium, reinforcing the potential of pulsed field ablation technology in treating complex cardiac arrhythmias.
The data were presented at the 31st Annual International AF Symposium in Boston from February 5 to 7, where the study was selected for a Late Breaking Clinical Trial session due to its scientific significance.
The Field PULSE study evaluates a high-voltage, sub-second pulsed field waveform delivered via the company’s FieldForce Ablation System, designed to enable rapid and precise tissue ablation without prolonged catheter contact.
Principal investigator Vivek Y. Reddy from Mount Sinai Hospital said the approach preserves procedural flexibility while improving efficiency.
“Sub-second energy delivery allows physicians to perform point-by-point ablation more effectively, without relying on extended tissue contact,” he explained.
Study findings showed that lesions were created in under 200 milliseconds, enabling faster procedures. The median time for pulmonary vein isolation was recorded at 12.5 minutes, with the quickest case completed in just 7.7 minutes.
Durability assessments also demonstrated strong outcomes, with isolation rates exceeding 94 per cent by vein and 84 per cent by patient.
From a safety perspective, no device-related serious adverse events were reported. There were also no cases of acute kidney injury, phrenic nerve damage, or clinically significant hemolysis. Brain MRI scans conducted on selected patients showed no evidence of silent cerebral lesions.
Field Medical Founder and Chief Technology Officer Steven Mickelsen said the results validate the company’s platform-based development strategy.
“Delivering each ablation point in a fraction of a second reduces dependence on catheter stability and limits the impact of cardiac motion,” he said.
He added that the technology supports a versatile treatment platform capable of addressing both atrial and ventricular arrhythmias with improved consistency and safety.
Field Medical is also participating in multiple scientific sessions at the symposium, including presentations on the biophysics of pulsed field ablation and live case demonstrations involving atrial fibrillation treatment.
The company believes that the Field PULSE findings mark a significant step forward in advancing minimally invasive cardiac therapies and strengthening the future of electrophysiology procedures.
-wilayah.com.my
